Annovis’ Alzheimer’s treatment helps improve cognition in trial

By Thomson Reuters Apr 29, 2024 | 9:29 AM

(Reuters) -Annovis Bio said on Monday its Alzheimer’s treatment showed significantly higher improvement in cognition in patients during a mid-stage trial.

The company’s drug buntanetap works by decreasing the production of amyloid beta protein, believed to be a hallmark of Alzheimer’s, from the brain.

Annovis plans to conduct a late-stage trial based on results of this trial.

(Reporting by Christy Santhosh; Editing by Vijay Kishore)